websites - Anika Arthrosurface Parcus Medical
Viscosupplementation injections are on the decline by 5% per year. In a bold strategic move, Anika is jumping into implants for joint arthritis and sports medicine for $195M. This will be very interesting to watch. Anika is a public company - ANIK.
The Arthrosurface acquisition is for an upfront payment of around $60 million, with an additional $40 million contingent upon achievement of certain regulatory and commercial milestones.
The Parcus Medical acquisition is for an upfront payment of approximately $35 million in cash, with an additional $60 million contingent upon achievement of certain commercial milestones
Anika Therapeutics to Acquire Parcus Medical and Arthrosurface (press release)
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has signed agreements to acquire Parcus Medical, a leading, privately-held sports medicine company, and Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active pat...
